The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

The global hemostasis products market is projected to grow from USD 1.94 billion in 2025 to USD 3.28 billion by 2035, at a CAGR of 5.41%. Growth is driven by increasing surgical procedures, trauma cases, and demand for advanced bleeding control technologies. However, high product costs and low reimbursement in developing nations pose challenges. Topical hemostats and sponge/pad forms dominate the market, while flowable hemostats and matrix/gel forms show fastest growth. North America leads with 41.62% market share, while Asia-Pacific is the fastest-growing region.

The global fibrin sealant market is projected to grow from USD 1.60 billion in 2025 to USD 3.57 billion by 2035 at a CAGR of 8.37%, driven by increasing surgical volumes, minimally invasive procedures, and expanding applications in trauma and wound care. However, high costs and insurance coverage limitations remain barriers to adoption in emerging markets.

Baxter International's stock fell 15.58% after the company reported mixed Q4 2025 earnings with a revenue beat but significant earnings miss. While sales rose 8% to $2.97 billion, non-GAAP net income dropped 24% to $0.44 per share, falling short of analyst expectations of $0.54 per share. The company's 2026 guidance forecasting flat to 1% sales growth and lower adjusted earnings per share ($1.85-$2.05 vs. $2.27 in 2025) further disappointed investors.

Baxter International reported fourth-quarter adjusted EPS of 44 cents, missing guidance of 52-57 cents and Wall Street estimates of 54 cents, primarily due to unfavorable product mix. While sales of $2.974 billion beat consensus expectations with 8% year-over-year growth, the company issued weak 2026 guidance with adjusted earnings of $1.85-$2.05 per share versus consensus of $2.25. Baxter shares fell 15.6% to $18.79, trading near 52-week lows.

Baxter International has cut its dividend significantly and faced a 75% stock decline over five years due to inconsistent revenue and negative earnings. However, the company's essential medical products, attractive valuation metrics, and strong demographic tailwinds from an aging population may appeal to turnaround and value investors, though recovery could be uneven and prolonged.

The global advanced wound closure market is projected to grow from USD 18.47 billion in 2025 to USD 32.54 billion by 2035, at a CAGR of 6.9%. Growth is driven by increasing surgical procedures, rising chronic wounds and diabetes cases, and technological innovations in surgical sealants, hemostats, and tissue adhesives. North America leads the market while Asia Pacific shows the highest growth potential.

The elastomeric infusion pumps market is projected to grow from USD 1.15 billion in 2025 to USD 1.49 billion by 2030 at a CAGR of 5.3%. Growth is driven by increased demand for reliable drug delivery systems in home healthcare and ambulatory care, rising chronic disease prevalence, and advancements in product design. North America leads the market, with continuous-rate pumps dominating the segment.

The global sodium chloride injection market is projected to grow from USD 544.12 million in 2025 to USD 870.21 million by 2032, with a CAGR of 6.93%. Growth is driven by clinical practice migration from inpatient to outpatient care, manufacturing modernization including modular aseptic technologies, and innovations in packaging and dosing formats. Key challenges include raw material costs and supply chain pressures, while manufacturers are investing in sterile capacities and service-oriented differentiation strategies.

Law firm investigating potential securities misconduct for Baxter International and Molina Healthcare following class action complaints alleging misleading statements about product safety and financial performance.

A class action lawsuit has been filed against Baxter International for allegedly misleading investors about systemic defects in their Novum LVP medical devices, which potentially exposed patients to serious injury risks.

A class action lawsuit has been filed against Baxter International for allegedly misleading investors about systemic defects in their Novum LVP medical devices, which potentially exposed patients to serious risks.